IP Verse

A Pharmaceutical Composition Comprising Metamizole, Drotaverine, And Caffeine - EP3749286

The patent EP3749286 was granted to Adamed Pharma on Oct 23, 2024. The application was originally filed on Feb 2, 2019 under application number EP19702616A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3749286

ADAMED PHARMA
Application Number
EP19702616A
Filing Date
Feb 2, 2019
Status
Granted And Under Opposition
Sep 19, 2024
Grant Date
Oct 23, 2024
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

MEDITOP GYOGYSZERIPARI KFTJul 21, 2025KOVARIADMISSIBLE

Patent Citations (17) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
INTERNATIONAL-SEARCH-REPORTRU2183116
INTERNATIONAL-SEARCH-REPORTRU2232018
INTERNATIONAL-SEARCH-REPORTWO0107024
INTERNATIONAL-SEARCH-REPORTWO2015089614
OPPOSITIONRU2183116
OPPOSITIONRU2232018
OPPOSITIONWO0107024
OPPOSITIONWO2015089614
OPPOSITIONWO2016075617
OTHEREP0749286
OTHEREP0993828
OTHEREP3749286
OTHERRU2232018
OTHERWO0107024
OTHERWO2010127205
OTHERWO2015089614
OTHERWO2016075617

Non-Patent Literature (NPL) Citations (17) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
INTERNATIONAL-SEARCH-REPORT- Anonymous, "Rezumatul caracteristicilor produsului", Romania, (20160401), URL: https://www.anm.ro/_/_RCP/rcp_3694_12.08.03.pdf, (20180713), XP055492592 [Y] 1-11,16 * page 8, paragraph 6.1. *-
INTERNATIONAL-SEARCH-REPORT- A S Gavrilov ET AL, "OPTIMIZATION OF THE COMPOSITION AND WET GRANULATION TECHNOLOGY OF DROTAVERINE HYDROCHLORIDE TABLETS Translated from Khimiko-Farmatsevticheskii", (20050501), pages 49 - 52, URL: https://link.springer.com/content/pdf/10.1007/s11094-005-0131-y.pdf, (20180716), XP055492821 [Y] 1-11,16 * page 277, column right, paragraph last * * abstract * * page 276, column right, paragraph penultimate *-
OPPOSITION- Anonymous , "ICH Topic Q 1 A (R2) Stability Testing of new Drug Substances and Products", EMA - European Medicines Agency, (20030801), pages 1 - 20, EMA - European Medicines Agency , URL: https://www.ema.europa.eu/en/documents/scientific-guideline/ich-q-1-r2-stability-testing-new-drug-substances-and-products-step-5_en.pdf, XP093303784-
OPPOSITION- Anonymous, "metamizole-containing medicinal products", European Medicines Agency - EMEA/H/A-31/1469, (20181213), pages 1 - 15, XP093303789-
OPPOSITION- Anonymous , "Metamizole", Wikipedia, (20250609), pages 1 - 15, Wikipedia , URL: https://en.wikipedia.org/w/index.php?title=Metamizole&oldid=1294684626, XP093303775-
OPPOSITION- A. S. Gavrilov ; E. V. Gusel'nikova ; A. Yu. Petrov, "Optimization of the Composition and Wet Granulation Technology of Drotaverine Hydrochloride Tablets", Pharmaceutical Chemistry Journal, (20050501), vol. 39, no. 5, ISSN 1573-9031, pages 274 - 277, XP019290487-
OPPOSITION- A.S. Gavrilov, "Optimization of the Composition and Wet Granulation Technology of Drotaverine Hydrochloride Tablets", Pharmaceutical Chemistry Journal, (200505), vol. 39, page 5-
OPPOSITION- D1b - the B1 publication of the opposed patent-
OPPOSITION- D1 -the authentic text of the opposed patent-
OPPOSITION- D2a - English translation of the claims of the priority document-
OPPOSITION- D2b - English translation of the description of the priority document-
OPPOSITION- D3 - the application as filed (PCT application body of the opposed patent-
OPPOSITION- D4 - SmPC of the Quarelin medicinal product (prior art, non-patent literature)-
OPPOSITION- Siew Adeline, "Tackling challenges in the development of fixed-dose combinations", Pharmaceutical Technology, (20140402), pages 1 - 4, Pharmaceutical Technology, URL: https://www.pharmtech.com/view/tackling-challenges-development-fixed-dose-combinations , XP093303782-
OTHER- A. S. Gavrilov ; E. V. Gusel'nikova ; A. Yu. Petrov, "Optimization of the Composition and Wet Granulation Technology of Drotaverine Hydrochloride Tablets", Pharmaceutical Chemistry Journal, Ne , (20050501), vol. 39, no. 5, ISSN 1573-9031, pages 274 - 277, XP019290487-
OTHER- Koo Otilia, "Manufacturing process considerations for fixed-dose combination drug products", Research Bristol-Myers Squibb (BMS), (20100401), Research Bristol-Myers Squibb (BMS), (20230103), XP093011417-
OTHER- Tiwari A. K., H. Shah, A. Rajpoot, Mammohan Singhal, "Formulation and In-Vitro evaluation of immediate release tablets of drotaverine HCI", J. Chem. Pharm. Res., (20110101), vol. 3, no. 4, pages 333 - 341, XP093011419-

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents